Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2914)
All Articles published online
|
Apr 27, 2010 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2010; 2(4): 139-142 [PMID: 21160985 DOI: 10.4254/wjh.v2.i4.139] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v2/i4/139.htm |
| Number | Citing Articles |
| 1 |
Venessa Pattullo, Mark W Douglas, Jacob George. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis?. Expert Review of Gastroenterology & Hepatology 2011; 5(2): 265 doi: 10.1586/egh.11.12
|
| 2 |
Dan-Qin Sun, Sheng-Jie Wu, Wen-Yue Liu, Qian-Di Lu, Gui-Qi Zhu, Ke-Qing Shi, Martin Braddock, Dan Song, Ming-Hua Zheng. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. Expert Opinion on Therapeutic Targets 2016; 20(3): 375 doi: 10.1517/14728222.2016.1096930
|
| 3 |
Xinyue Lin, Juanhong Zhang, Yajun Chu, Qiuying Nie, Junmin Zhang. Berberine prevents NAFLD and HCC by modulating metabolic disorders. Pharmacology & Therapeutics 2024; 254: 108593 doi: 10.1016/j.pharmthera.2024.108593
|
| 4 |
Michael S Kostapanos, Anastazia Kei, Moses S Elisaf. Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World Journal of Hepatology 2013; 5(9): 470-478 doi: 10.4254/wjh.v5.i9.470
|
| 5 |
Juan P Arab, Roberto Candia, Rodrigo Zapata, Cristián Muñoz, Juan P Arancibia, Jaime Poniachik, Alejandro Soza, Francisco Fuster, Javier Brahm, Edgar Sanhueza, Jorge Contreras, M Carolina Cuellar, Marco Arrese, Arnoldo Riquelme. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World Journal of Gastroenterology 2014; 20(34): 12182-12201 doi: 10.3748/wjg.v20.i34.12182
|
| 6 |
Stergios A. Polyzos, Jannis Kountouras, Christos Zavos, Georgia Deretzi. Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2012; 46(4): 272 doi: 10.1097/MCG.0b013e31824587e0
|
| 7 |
Theodosios D. Filippatos, Evangelos N. Liberopoulos, Moses S. Elisaf. Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 2015; 6(1): 29 doi: 10.1177/2042018814558243
|
| 8 |
Theodosios D. Filippatos. A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 2012; 26(3): 245 doi: 10.1007/s10557-012-6394-0
|
| 9 |
Klementina Fon Tacer, Damjana Rozman. Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation. Journal of Lipids 2011; 2011: 1 doi: 10.1155/2011/783976
|
| 10 |
Theodosios D Filippatos, Moses S Elisaf. Role of ezetimibe in non-alcoholic fatty liver disease. World Journal of Hepatology 2011; 3(10): 265-267 doi: 10.4254/wjh.v3.i10.265
|
| 11 |
Stergios A Polyzos, Jannis Kountouras, Efthimia Zafeiriadou, Kalliopi Patsiaoura, Evangelia Katsiki, Georgia Deretzi, Christos Zavos, Georgios Tsarouchas, Pantelitsa Rakitzi, Aristidis Slavakis. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. Journal of the Renin-Angiotensin-Aldosterone System 2011; 12(4): 498 doi: 10.1177/1470320311402110
|
| 12 |
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos, Moses S. Elisaf. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012; 61(7): 906 doi: 10.1016/j.metabol.2011.12.002
|
| 13 |
Niki Katsiki, Moses Elisaf. Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease. Current Medical Research and Opinion 2011; 27(8): 1669 doi: 10.1185/03007995.2011.596410
|
| 14 |
Peng Cheng, Sheng Sheng Yang, Xian Gui Hu, Xu Yu Zhou, Yi Jie Zhang, Gang Jin, Ying Qi Zhou. Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alpha. FEBS Letters 2011; 585(21): 3403 doi: 10.1016/j.febslet.2011.09.043
|
| 15 |
A. N. Mavrogiannaki, I. N. Migdalis. Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data. International Journal of Endocrinology 2013; 2013: 1 doi: 10.1155/2013/450639
|
| 16 |
Wu-wen Feng, Shuang-yu Kuang, Can Tu, Zhi-jie Ma, Jing-yao Pang, Yan-hui Wang, Qing-ce Zang, Ta-si Liu, Yan-ling Zhao, Xiao-he Xiao, Jia-bo Wang. Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin. Biomedicine & Pharmacotherapy 2018; 99: 325 doi: 10.1016/j.biopha.2018.01.071
|
| 17 |
Letícia F Ramos, Caio M Silva, Camila C Pansa, Karen C M Moraes. Non-alcoholic fatty liver disease: molecular and cellular interplays of the lipid metabolism in a steatotic liver. Expert Review of Gastroenterology & Hepatology 2021; 15(1): 25 doi: 10.1080/17474124.2020.1820321
|
| 18 |
Anastazia A. Kei, Theodosios D. Filippatos, Moses S. Elisaf. The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 2016; 15(4): 559 doi: 10.1517/14740338.2016.1157164
|